Key facts
- This page summarizes David Pendarvis's Form 4 filing for RESMED INC (RMD).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 04 Nov 2022, 11:34.
David Pendarvis - 03 Nov 2022 Form 4 Insider Report for RESMED INC (RMD)
- Reporting relationship
- Chief Administrative Officer
- Issuer ticker
- RMD
- Reported as of
- 03 Nov 2022
- Net transaction value
- -$332,530
- SEC form
- 4
- Accepted by SEC
- 04 Nov 2022, 11:34:47 UTC
- Prior SEC filing
- 05 Oct 2022
- Next SEC filing
- 15 Nov 2022
- Source filing
- View source filing
- Reporting owner signature
- David Pendarvis, Chief Administrative Officer
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David Pendarvis filed Form 4 for RESMED INC (RMD) on 04 Nov 2022.
Change
- Previous filing in this sequence was filed on 05 Oct 2022.
- Current net transaction value: -$332,530.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RMD
transaction
ResMed Common Stock
Sale
- Transaction value
- $332,530
- Shares
- -1,545
- Change %
- -1.5%
- Price
- $215.23
- Shares after
- 102,334
- Date
- 03 Nov 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The transaction was conducted under a Rule 10b5-1 plan.